PL MLP

Drug Profile

PL MLP

Alternative Names: LPMX-1; LPMX-2; PL-MLP; Promitil

Latest Information Update: 23 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Lipomedix Pharmaceuticals
  • Class Antineoplastics; Cytostatic antibiotics
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Colorectal cancer; Solid tumours
  • Preclinical Bladder cancer

Most Recent Events

  • 23 Jul 2018 PL MLP is still in phase I trials for Solid-tumours (Late-stage disease) in Israel
  • 11 Jun 2018 LipoMedix has patent protection for Promitil®
  • 01 Jun 2018 Lipomedix Pharmaceuticals completes a phase I trial in Solid tumours (Late-stage disease) in Israel (NCT01705002)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top